Abbreviations & Acronyms BPH = benign prostatic hyperplasia DRE = digital rectal examination F = flat LUTS = lower urinary tract symptoms LUTS/BPH = lower urinary tract symptoms suggestive of benign prostatic hyperplasia Ma = markedly enlarged Mo = moderately enlarged N = normal PV = prostate volume S = slightly enlarged TRUS = transrectal ultrasound Objectives: To investigate the accuracy of digital rectal examination in estimating prostate volume in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Methods: A community-based study was carried out in Japan to investigate the prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. A total of 457 men were screened and deemed eligible for the present analysis. Findings on digital rectal examination were compared with prostate volume measurement by transrectal ultrasound. Five groups were identified on digital rectal examination: flat, normal, slightly enlarged, moderately enlarged and markedly enlarged. Results: The median age and prostate volume were 64 years and 19.7 mL, respectively. Prostate volumes for the flat, normal, slightly enlarged, moderately enlarged, and markedly enlarged groups were 16.4, 18.3, 27.0, 41.9 and 86.3 mL, respectively. There were significant differences in prostate volume between the groups. The positive predictive value was 94.1% if flat, and normal were assumed to have a prostate volume <30 mL. The value was 80.8% if moderately enlarged, and markedly enlarged were assumed to have a prostate volume ≥30 mL. Of the men in the slightly enlarged group, 61.0% had a prostate volume <30 mL. Conclusions: It is possible to stratify prostate volume according to digital rectal examination. We could determine the prostates in the flat and normal groups to have a prostate volume <30 mL, and those in the moderately enlarged and markedly enlarged groups to have a prostate volume ≥30 mL by digital rectal examination with high accuracy. Transrectal ultrasound was required for those in the slightly enlarged group.
Introduction
For patients with LUTS/BPH, it is important for clinicians who make the treatment decision to determine whether the PV is >0 mL. In a report by Jacobsen et al. about the natural history of BPH, men with a PV of >30 mL had a threefold increase in the risk of urinary retention and a ninefold increase in the risk for needing surgery related to BPH. 1, 2 Crawford et al. reported that a PV of ≥31 mL was one of the important predictors for the risk of clinical progression of BPH, including progression of the International Prostate Symptoms Score, the occurrence of urinary retention and development to an invasive procedure. 3 For the BPH patient who has an enlarged prostate with a size >30 mL, previous large clinical trials such as the MTOPS trial and CombAT trial showed the effectiveness of combination therapy with a 5-a-reductase inhibitor and an ablocker. 4, 5 Although the risks and treatment for the enlarged prostate have been reported, there have not been many reports on evaluation of the PV. Currently, there is no convenient method to evaluate the PV other than by ultrasonographic examination. Abdominal ultrasound and TRUS are simplified, non-invasive methods, but they need time and labor. It would very useful if a routine examination for BPH/LUTS, such as DRE, could predict the PV instantly. We therefore surveyed the accuracy of DRE to estimate PV of >30 mL.
Methods
We carried out community-based studies in Shimamaki-mura, Japan, in 1992-1993 and 2007-2008 to investigate the prevalence of LUTS/BPH. 6 Of the 533 men who underwent medical examinations, 457 were eligible for this study. Examinees who had a past history of prostate cancer or undergoing prostate procedures were excluded. We compared the results of DRE with the PV measurement by TRUS and evaluated the concordance rate. The medical examinations were carried out by three urologists. We classified the results of DRE into five groups: F, N, S, Mo and Ma. The PV was estimated using an ellipsoid formula: longitudinal diameter 9 transverse diameter 9 anteroposterior diameter 9 p/6. TRUS was carried out with a Bruel and Kjaer transrectal ultrasonograph having a type 8551 (7.0 MHz) endosonic multiplane transducer. The median PVs of the groups categorized by DRE were compared using the Mann-Whitney U-test. The accuracy of the diagnostic test was presented as positive and negative predictive values with 95% confidence intervals. Correlation coefficient values were calculated to compare the correlation of the PV measurements with DRE. Scores of 0.41-0.60 were considered to have a moderate correlation, 0.61-0.80 a strong correlation and 0.81-0.99 a very strong correlation. Age, PSA and individual TRUS dimensions were compared with the PV cut-off level of 30 mL by using paired t-tests. A P-value of <0.05 was considered statistically significant.
Results
The median age and PV were 64 years (range 40-93 years) and 19.7 mL (range 7.4-116.6 mL), respectively. The examinees were classified into F, n = 57; N, 297; S, 77; Mo, 21; and Ma, 5 ( Table 1 ). The median PVs were F, 16.4 mL; N, 18.3 mL; S, 27.0 mL; Mo, 41.9 mL; and Ma, 86.3 mL. There were significant differences between groups (P < 0.001; Table 2 ). The median PSA levels were F, 0.6 ng/mL; N, 0.9 ng/mL; S, 1.5 ng/mL; Mo, 2.9 ng/mL; and Ma, 7.4 ng/mL. There were significant differences between groups except for group Mo versus Ma (P = 0.079; Table 2 ). Of the examinees, 385 had PV <30 mL and 72 had PV ≥30 mL. The positive predictive value was 94.1% if groups F and N were assumed to have PV <30 mL, but the positive predictive value was 49.5% if groups S, Mo and Ma were assumed to have PV ≥30 mL. The positive predictive value rose to 80.8% if groups Mo and Ma were assumed to have PV ≥30 mL. Sixty-one percent of group S had PV <30 mL. Figure 1 shows a box-and-whisker plot stratifying the PVs according to DRE, and the 30 mL cut-off level. Only group S was distributed across the 30 mL cut-off level.
In group S, there were significant differences in all variables except for age between above and below the 30 mL cut-off level (Table 3 ). The highest correlation was seen between PV and anteroposterior diameter (correlation coefficient value 0.79).
Discussion
DRE is commonly carried out to evaluate the prostate in men who have LUTS, and is recommended by several guidelines. [7] [8] [9] It also plays an important role in excluding malignancy.
We categorized the prostates into five groups according to the prostate size evaluated by DRE. There have been several reports about the comparison of the PV with DRE directly, but the accuracy of the subjective impression of DRE in the five-grade evaluation that urologists carry out daily has not been reported. [10] [11] [12] We believe that the present results are more realistic with regard to clinical practice than those of other reports.
In the present study, there were significant differences among the groups categorized by DRE. We found that it was possible to stratify PV according to DRE. Previous studies have reported the sensitivity and specificity of DRE to predict PV. [10] [11] [12] [13] Bosch et al. reported that the sensitivity and specificity of the PV 30 mL cut-off level were 94.3% and 78.2%, respectively. In contrast, Michael et al. reported that these values were 39.8% and 81.6%, respectively. Though the results varied somewhat, the majority of them reported that DRE tended to underestimate PV. 12, 13 Roehrborn et al. reported that PV tended to be underestimated by DRE, because impalpable areas existed on the bilateral prostate. 13 In the present study, we categorized the PV into five groups by DRE. In contrast, a previous report used a unique method of DRE to increase diagnostic accuracy for estimation of PV. Reis et al. reported standardizing the DRE by the convenient means of fingertips. 14 They showed that the positive predictive value to identify PV above 30 mL was 92.3%, despite the DRE being carried out by medical students. In contrast Loeb et al. showed that DRE correlated poorly when estimated by multiple examiners with no previous standardization. 15 These reports showed the necessity of standardizing DRE. As the standardization of DRE progresses, its accuracy should increase.
Although PSA as a volume marker is influenced by other factors, including age, malignancy and 5-a-reductase inhibitor, previous studies have assessed its reliability as a predictor of PV if malignancy is excluded. [16] [17] [18] In the present study, there were significant differences in PSA between the groups except for group Mo versus Ma (P = 0.079).
In group S, the PV was not predicted to be over or under 30 mL by DRE. The PV in group S correlated more highly with anteroposterior diameter than longitudinal and transverse diameter. The anteroposterior diameter, which is impalpable, did not lead to correct prediction of the volume. Therefore, this group needed TRUS, but the PSA level was useful as an alternative predictor. The positive predictive value was 88.0% if a PSA level <1.0 ng/mL was assumed to indicate PV <30 mL. The positive predictive value was 83.3% if a PSA level ≥4.0 ng/mL was assumed to indicate PV ≥30 mL.
In the present study, the examiners who carried out DRE were trained urologists. Cheng et al. reported the accuracy of estimating the PV with DRE by urological staff members with different levels of experience. 19 The difference between the PV measured with TRUS and that estimated with DRE was statistically significant only between a junior urology trainee (2 months working experience) and a trained urologist (>5 years working experience; P = 0.003). There was no significant difference between a senior urology trainee (20 months working experience) and the trained urologist. We therefore believe that DRE is a reliable tool to estimate PV if the examiner is not a junior urology trainee.
The present study had a limitation and a strength. Despite the large sample size, just three trained urologists evaluated the PVs with DRE in the present study. In addition, each examinee underwent DRE by only one examiner. Therefore, we could not determine the interrater reliability in the present study. However, it was not realistic to carry out DRE on one examinee by several urologists, because it was too invasive to do repeatedly.
It is possible to stratify PV according to DRE. We could determine the prostates in groups F and N to have PV <30 mL, and those in groups Mo and Ma to have PV ≥30 mL by DRE with high accuracy. TRUS was required for prostates in group S to estimate whether the PV was ≥30 mL or not, because over half of them in this group were <30 mL. 
